Free Trial

STERIS (STE) Competitors

STERIS logo
$241.58 +0.94 (+0.39%)
Closing price 10/7/2025 03:59 PM Eastern
Extended Trading
$244.90 +3.32 (+1.38%)
As of 08:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STE vs. BDX, IDXX, EW, RMD, DXCM, PODD, HOLX, BAX, MASI, and GMED

Should you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), Edwards Lifesciences (EW), ResMed (RMD), DexCom (DXCM), Insulet (PODD), Hologic (HOLX), Baxter International (BAX), Masimo (MASI), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry.

STERIS vs. Its Competitors

Becton, Dickinson and Company (NYSE:BDX) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Becton, Dickinson and Company has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, STERIS has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.

In the previous week, Becton, Dickinson and Company had 15 more articles in the media than STERIS. MarketBeat recorded 29 mentions for Becton, Dickinson and Company and 14 mentions for STERIS. STERIS's average media sentiment score of 1.78 beat Becton, Dickinson and Company's score of 1.59 indicating that STERIS is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Becton, Dickinson and Company
27 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
STERIS
13 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Becton, Dickinson and Company has higher revenue and earnings than STERIS. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and Company$20.18B2.74$1.71B$5.5634.63
STERIS$5.46B4.36$614.64M$6.5337.00

STERIS has a net margin of 11.61% compared to Becton, Dickinson and Company's net margin of 7.51%. Becton, Dickinson and Company's return on equity of 16.23% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
Becton, Dickinson and Company7.51% 16.23% 7.46%
STERIS 11.61%14.17%9.25%

Becton, Dickinson and Company currently has a consensus price target of $205.40, suggesting a potential upside of 6.67%. STERIS has a consensus price target of $273.50, suggesting a potential upside of 13.21%. Given STERIS's stronger consensus rating and higher possible upside, analysts clearly believe STERIS is more favorable than Becton, Dickinson and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Becton, Dickinson and Company
0 Sell rating(s)
9 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25
STERIS
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78

Becton, Dickinson and Company pays an annual dividend of $4.16 per share and has a dividend yield of 2.2%. STERIS pays an annual dividend of $2.52 per share and has a dividend yield of 1.0%. Becton, Dickinson and Company pays out 74.8% of its earnings in the form of a dividend. STERIS pays out 38.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Becton, Dickinson and Company has raised its dividend for 53 consecutive years and STERIS has raised its dividend for 20 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

87.0% of Becton, Dickinson and Company shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 0.4% of Becton, Dickinson and Company shares are owned by company insiders. Comparatively, 1.1% of STERIS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

STERIS beats Becton, Dickinson and Company on 13 of the 19 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for STE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STE vs. The Competition

MetricSTERISMED INSTRUMENTS IndustryMedical SectorNYSE Exchange
Market Cap$23.70B$7.07B$6.12B$22.14B
Dividend Yield1.05%1.15%5.70%3.57%
P/E Ratio37.0027.2985.6629.64
Price / Sales4.36201.06622.8895.37
Price / Cash16.8822.0037.7824.65
Price / Book3.595.2713.214.61
Net Income$614.64M$178.04M$3.30B$1.01B
7 Day Performance0.18%3.60%3.95%-0.14%
1 Month Performance-2.75%10.60%8.40%2.28%
1 Year Performance6.32%32.96%88.36%14.59%

STERIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STE
STERIS
4.8806 of 5 stars
$241.58
+0.4%
$273.50
+13.2%
+6.9%$23.70B$5.46B37.0017,787Positive News
BDX
Becton, Dickinson and Company
4.9399 of 5 stars
$183.85
-0.4%
$213.09
+15.9%
-18.9%$52.91B$20.18B33.0774,000Positive News
IDXX
IDEXX Laboratories
4.261 of 5 stars
$630.56
-0.3%
$649.44
+3.0%
+32.8%$50.58B$3.90B52.5011,000Positive News
EW
Edwards Lifesciences
4.8748 of 5 stars
$77.25
+1.3%
$86.61
+12.1%
+18.8%$44.77B$5.44B11.1115,800Positive News
Analyst Upgrade
Short Interest ↓
RMD
ResMed
4.5344 of 5 stars
$271.22
+0.4%
$294.20
+8.5%
+22.0%$39.57B$5.15B28.5210,600Positive News
DXCM
DexCom
4.9571 of 5 stars
$66.46
-1.0%
$99.11
+49.1%
-3.8%$26.31B$4.03B46.1510,300Analyst Forecast
PODD
Insulet
4.7385 of 5 stars
$310.62
-2.3%
$345.76
+11.3%
+37.6%$22.38B$2.07B94.413,900
HOLX
Hologic
4.8084 of 5 stars
$67.15
-0.1%
$79.38
+18.2%
-15.2%$14.95B$4.03B27.867,063Analyst Forecast
BAX
Baxter International
4.7257 of 5 stars
$22.36
+1.7%
$30.11
+34.7%
-36.0%$11.29B$10.64B-74.5238,000Analyst Forecast
Options Volume
MASI
Masimo
4.4776 of 5 stars
$142.94
+1.1%
$194.60
+36.1%
+10.7%$7.68B$2.09B-16.785,600Analyst Downgrade
GMED
Globus Medical
4.922 of 5 stars
$56.49
+1.4%
$87.64
+55.1%
-15.1%$7.52B$2.52B21.735,300

Related Companies and Tools


This page (NYSE:STE) was last updated on 10/8/2025 by MarketBeat.com Staff
From Our Partners